Europe's ATMP Ambition Is Clear. Execution Is the Real Challenge.
From pioneering cell and gene therapies to world-leading academic research, Europe has consistently demonstrated its ability to innovate. Now, with the EU Biotech Act placing health innovation firmly on the political agenda and the 2026 Horizon Europe Health Calls preparing fresh funding opportunities, Europe has a genuine opportunity to strengthen its position in the global advanced therapies landscape.
To explore these challenges, Phacilitate and BIOCAT brought together senior leaders from across policy, biotech and industry for an in-depth discussion on the future of Europe's ATMP ecosystem.
)
Watch the Discussion On Demand
To explore these challenges, Phacilitate brought together senior leaders from across policy, biotech and industry for an in-depth discussion on the future of Europe's ATMP ecosystem.
The webinar examines the practical realities behind today's policy announcements and asks what must happen next to ensure Europe remains competitive.
The discussion explores:- Europe's execution gap and what is preventing faster progress
- What the EU Biotech Act could mean for innovation, manufacturing and health sovereignty
- How the 2026 Horizon Europe Health Calls may reshape clinical trial activity
- The structural barriers limiting Europe's competitiveness
- The actions needed to accelerate innovation and improve patient access
Whether you missed the live session or would like to revisit the conversation, you can now watch the full webinar on demand.
Hear From Industry Leaders
The discussion features perspectives from leaders working across every part of the advanced therapies ecosystem:
- Montse Daban Marin, Director of Strategy & Global Partnerships, Biocat
- Miguel Forte, CEO, Kiji Therapeutics
- Paolo Morgese, VP Public Affairs Europe, Alliance for Regenerative Medicine
- Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult
- Jim Lund, Chief Business Development Officer, CCRM Nordic
Together, they explore not only where Europe stands today, but what the industry must prioritise over the coming months to remain globally competitive.
The Conversation Continues This September
While the webinar provides valuable insight into Europe's evolving landscape, it also sets the stage for a much broader conversation.
From 7 to 9 September 2026, senior leaders from biotech, pharma, academia, investment, manufacturing, regulation and technology will come together at Advanced Therapies Europe 2026 in Barcelona to continue these discussions in person.
Across three days of curated networking, strategic debate and practical case studies, attendees will explore the commercial, clinical and operational challenges shaping the future of advanced therapies in Europe.
Topics include regulatory evolution, manufacturing scale-up, clinical development, investment, market access and commercialisation, with opportunities to engage directly with the organisations driving change across the ecosystem.
If the themes discussed in this webinar are priorities for your organisation, Advanced Therapies Europe is where those conversations continue.
Watch the webinar on demand today, then join us in Barcelona this September to help shape what's next for Europe's advanced therapies industry.
